AWKN002

AWKN002 is a proprietary **oral thin film formulation of esketamine hydrochloride** being developed by **Awakn Life Sciences** for **moderate to severe alcohol use disorder**. The product delivers **esketamine**, the S-enantiomer of ketamine, by **sublingual and buccal administration** and is intended for use alongside structured psychosocial support such as alcohol education or cognitive behavioral therapy. Esketamine acts primarily as an **N-methyl-D-aspartate receptor antagonist**, producing rapid neuropsychiatric effects including dissociation, and in early clinical work this formulation was reported to be well tolerated and associated with reductions in alcohol craving versus placebo. AWKN002 is a **small molecule reformulation** of esketamine being advanced via an FDA **505(b)(2)** regulatory pathway and has been described as being in **Phase 2 planning/in development** for alcohol use disorder.

Other names

esketamine hydrochloride oral thin filmesketamine oral thin filmS-ketamine oral thin film